US 12,187,712 B2
Cardiac sarcomere inhibitors
Bradley P. Morgan, South San Francisco, CA (US); Mark Vanderwal, Oakland, CA (US); and Chihyuan Chuang, Millbrae, CA (US)
Assigned to CYTOKINETICS, INC., South San Francisco, CA (US)
Appl. No. 17/255,379
Filed by Cytokinetics, Inc., South San Francisco, CA (US)
PCT Filed Jun. 25, 2019, PCT No. PCT/US2019/038908
§ 371(c)(1), (2) Date Jul. 15, 2021,
PCT Pub. No. WO2020/005888, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/690,249, filed on Jun. 26, 2018.
Prior Publication US 2021/0276991 A1, Sep. 9, 2021
Int. Cl. C07D 413/14 (2006.01); C07D 271/06 (2006.01); C07D 413/12 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 271/06 (2013.01); C07D 413/12 (2013.01)] 39 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or halo;
G1 is —N— or —C(Rb)—, wherein Rb is H or halo;
R2 is H or —CH3;
L1, Y1, and Y2 are defined by (i) or (ii):
(i) L1 is absent;
Y1 is Rx; and
Y2 is Rz;
or
(ii) L1

OG Complex Work Unit Chemistry
 wherein L2 is absent, —O—, —NH—, or —OCH2—*, and wherein * indicates the attachment to Y2;
Y1 is

OG Complex Work Unit Chemistry
 wherein R1aa is H, alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl; and
Y2 is —CH3, phenyl, or Rz;
Rx is

OG Complex Work Unit Chemistry
R1a, R1b, R1c1, R1c2, R1f, R1g, R1h1, and R1h2 are each independently H, alkyl, alkenyl, alkynyl, haloalkyl, —C(O)O-alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
R1d1, R1d2, and R1d3 are each independently alkyl, alkenyl, alkynyl, —C(O)O— alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
R1e1 and R1e2 are each independently H, alkyl, alkenyl, alkynyl, haloalkyl, —C(O)O-alkyl, or a cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring;
Rz is

OG Complex Work Unit Chemistry
R2a, R2b1, R2b2, R2c, R2d1, R2g2, R2h, R2i, and R2j are each independently selected from the group consisting of H, halo, —OH, —CN, —NRcRd, alkyl, alkenyl, alkynyl, —O-alkyl, haloalkyl, cycloalkyl, and —C(O)NRcRd;
R2e, R2f, R2g1, and R2g2 are each independently selected from the group consisting of halo, —OH, —CN, —NRcRd, alkyl, alkenyl, alkynyl, —O-alkyl, haloalkyl, cycloalkyl, and —C(O)NRcRd; and
Rc and Rd are each independently H or alkyl;
wherein, when Y1 is

OG Complex Work Unit Chemistry
 at least one of (a)-(c) applies:
(a) R2 is —CH3;
(b) R1 is halo; and
(c) G1 is —C(Rb)—, wherein Rb is halo; and
when Y1 is

OG Complex Work Unit Chemistry
 and Y2 is

OG Complex Work Unit Chemistry
 R2b1 is selected from the group consisting of H, halo, —OH, —CN, —NRcRd, alkyl, alkenyl, alkynyl, —O—C2-C6alkyl, haloalkyl, cycloalkyl, and —C(O)NRcRd.